Skip to Content

Can Descovy be used for pre-exposure prophylaxis (PrEP) in HIV?

Medically reviewed by Last updated on Oct 3, 2019.

Official Answer


Yes. The FDA approved Descovy (emtricitabine and tenofovir alafenamide) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection in October 2019.

Descovy was first approved in April 2016 in combination with other antiretoviral drugs to treat HIV-1 infection in adults and pediatric patients 12 years of age and older.

PrEP is an HIV prevention method in which people who do not have HIV take medicine on a daily basis to reduce their risk of getting HIV if they are exposed to the virus.

Descovy for PrEP is indicated for use in at-risk, adult and adolescent HIV-negative men and transgender women (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection.

Descovy is the second medicine to be FDA approved for PrEP, after the approval of Truvada (emtricitabine and tenofovir disoproxil fumarate) in July 2012.

See Medications for Pre-Exposure Prophylaxis

Related Medical Questions

Drug Information

Related Support Groups